The Blood Tests That Get More Interesting After 40

Your annual labs may look almost exactly like they did at 32. What they can tell you about the next 20 years is what’s changing.

There’s a little ritual most of us do after bloodwork.

You open the patient portal. You scroll past a wall of acronyms. You scan for anything in red.

Nothing red? Excellent. Close the tab. Carry on with your life.

And for a long time, that works fine. Somewhere around midlife, though, it becomes a surprisingly unsophisticated way to read your own health information.

A lab’s reference range answers one narrow question: is this result outside what the lab considers typical? It doesn’t answer the more interesting one: has something changed in me?

A fasting glucose that’s crept up over several years. Triglycerides quietly climbing. Hemoglobin drifting down. Kidney filtration edging lower. Each of those can show up with no red flag next to it at all. The individual number matters. So does the trajectory.

Which means metabolic screening doesn’t wait until something feels wrong. It starts while you feel completely fine.

The reference range is not a report card

The easiest mistake to make with bloodwork is sorting every result into “normal” or “abnormal.” Biology isn’t that tidy.

Reference ranges come from measurements in a reference population. They help clinicians spot unusual results, but they aren’t dividing lines between healthy and unhealthy. Context changes what a number means: your age, your sex, your medications, whether you fasted, whether you’re hydrated, whether you just had the flu or a brutal workout. For some measurements, the right target depends on your cardiovascular risk or medical history, not on whether you landed inside the printed range.

That’s worth remembering the next time someone online announces the one “perfect” number for everybody. There usually isn’t one.

Glucose is a snapshot. A1C is closer to a short documentary.

Fasting glucose tells you what your blood sugar was on the morning you got poked. A1C reflects your average glucose exposure over roughly the previous two to three months.

That matters because type 2 diabetes rarely appears overnight. Glucose regulation tends to slide gradually. The ADA considers an A1C below 5.7% outside the prediabetes range, 5.7% to 6.4% prediabetes, and 6.5% or higher in the diabetes range, and a diagnosis generally needs confirmation unless someone has unmistakable high blood sugar. A1C also has real limits: conditions that affect red blood cells or hemoglobin can throw it off, which is why clinicians don’t read it alone.

So the interesting question after 40 isn’t only “do I have diabetes?” It’s “which direction am I moving?” Noticing metabolic drift years before you arrive anywhere is the whole point of testing early.

Your cholesterol panel isn’t a two-character play

Most of us learned cholesterol as a morality tale. LDL is the villain, HDL is the hero, roll credits.

The real story is more nuanced. A standard lipid panel reports total cholesterol, LDL, HDL and triglycerides, and those numbers mean more when they’re read alongside your blood pressure, diabetes status, smoking history, age and other risk factors. That’s why two people with the same LDL can get different advice.

For adults 40 to 75, decisions about preventive medication increasingly depend on overall cardiovascular risk, not one cholesterol result floating alone. The U.S. Preventive Services Task Force, for example, bases its statin recommendations for primary prevention on a mix of risk factors and estimated 10-year cardiovascular risk.

So swap “is my LDL normal?” for “what does my whole cardiovascular picture say?” It’s a much better conversation to have.

The quiet one: your kidneys

Your comprehensive metabolic panel almost certainly includes creatinine. The more useful sidekick is eGFR, an estimate of how well your kidneys are filtering your blood, calculated from creatinine and other information.

Here’s the number that surprises people. The National Kidney Foundation estimates that more than 37 million U.S. adults have chronic kidney disease, and about 90% of them don’t know it. Kidney disease is very good at staying quiet. It usually doesn’t cause symptoms until later stages.

It also shows why one result isn’t a verdict. Kidney function is interpreted in context and often over time. For people at risk, clinicians may add a urine test called a urine albumin-to-creatinine ratio, because kidney damage and kidney filtration are two different questions. Boring-looking numbers, it turns out, can be very interesting long before you feel anything.

The CBC is quietly doing a lot of work

The complete blood count is one of the least glamorous tests on the page and one of the most information-dense. It looks at red blood cells, hemoglobin, hematocrit, white blood cells and platelets. Think of it less as a test for a specific disease and more as a census.

Are there enough red cells carrying oxygen? Are white cell counts behaving? Have platelets changed? Has hemoglobin shifted? When something moves, the CBC rarely tells you why. It tells you where another question might be worth asking.

This is where your history becomes useful. A value that’s technically in range but has been moving one direction for years can tell a clinician more than any single measurement. Your old bloodwork isn’t clutter. It’s your baseline.

“Liver tests” aren’t really liver tests

ALT. AST. Alkaline phosphatase. Bilirubin. They get lumped together and casually called liver function tests, but they don’t all measure the same thing, and some aren’t exclusive to the liver.

ALT and AST can rise when liver cells are injured, though AST also lives in tissues like muscle. Alkaline phosphatase can point to the liver or bile ducts, but also to bone. Bilirubin comes from the breakdown of red blood cells, which the liver then processes. Medications, alcohol, supplements, illness, hard exercise and metabolic conditions can all nudge pieces of this panel.

So a slightly abnormal result isn’t a diagnosis. It’s a clue. The useful question isn’t “is my liver good or bad?” It’s which number changed, by how much, and what else was going on when it did?

Then there’s the list everyone on the internet says you “need”

Vitamin D. B12. Ferritin. Iron studies. TSH and free T4. Testosterone. Estradiol. CRP. Insulin. Cortisol.

Depending on your corner of the internet, someone has told you that one of these explains why you’re tired, why your weight changed, why your hair changed, why you can’t sleep, why you can’t build muscle, or why you don’t feel 28 anymore.

Some of these tests can be extremely useful when there’s a reason to order them. That last part matters. Testing isn’t automatically better just because we can test more things. Whether a result means something depends partly on why it was ordered in the first place.

Thyroid testing is a good example. TSH is extremely useful when thyroid disease is suspected. But for asymptomatic, nonpregnant adults, the USPSTF says the evidence is insufficient to weigh the benefits and harms of screening, and it notes the risks of false positives and overdiagnosis and overtreatment. Many professional groups also recommend repeating a mildly abnormal thyroid result before making a diagnosis.

The same habit works for anything new in wellness, peptides included: ask what has actually been studied, in whom, and in what form. More data isn’t automatically more knowledge. Interpretation is what turns data into knowledge.

The test that doesn’t need a needle

One measurement belongs in this conversation, and it doesn’t require blood: blood pressure.

It’s easy to underestimate because it isn’t exotic. There’s no colorful dashboard of biomarkers. It’s also one of the most consequential numbers in preventive medicine, and high blood pressure affects about 45% of U.S. adults.

The USPSTF recommends blood pressure screening for all adults and suggests annual screening for adults 40 and older, or earlier for people at increased risk. And here’s the detail worth knowing: an elevated reading in the office should generally be confirmed with measurements taken outside the clinic, with a home monitor or an ambulatory device, before anyone diagnoses you. “White coat” nerves are real, and so is the opposite. The useful information isn’t always the fancy information.

So what do you do with your annual labs?

Not “build your own diagnosis from Google.” And not “ignore everything because the doctor’s office didn’t call.”

There’s a useful middle. When your new results come in, pull up the old ones too, ideally a few years’ worth. Notice what’s stayed remarkably steady and what hasn’t. Bring changes to your clinician, especially when they line up with symptoms, medications, family history or other risk factors.

And ask one really good question: “Is there anything here that’s still in range but has changed enough over time that you want to keep an eye on it?”

That beats asking whether every number is “good.” It turns a lab report from a pass/fail exam into what it actually is: a set of measurements taken at one moment in a much longer story. After 40, the story is usually more interesting than the snapshot.

Do this week

1. Pull up your last two or three sets of results. Most patient portals keep them. Just look at them side by side.

2. Look for direction, not just flags. Pick a few results that appear repeatedly in your bloodwork and compare them across several years. Up, down or steady? You don’t need to interpret the changes yourself—the point is to notice them.

3. Bring one question to your next appointment. The “still in range but changed” question works nicely.

4. Check your blood pressure outside the clinic. If your office reading has ever run high, ask your clinician whether home monitoring makes sense.

This article is for education and does not provide medical advice or recommend specific laboratory testing. Appropriate screening and interpretation depend on individual symptoms, medical history, medications and risk factors.

Sources & Further Reading

1. American Diabetes Association. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care, 2026.
Screening recommendations for diabetes and prediabetes, including testing beginning no later than age 35.

2. U.S. Preventive Services Task Force. Hypertension in Adults: Screening.
Blood pressure screening, screening intervals, and confirming a diagnosis outside the office.

3. U.S. Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication.
How preventive decisions rely on overall cardiovascular risk, not one cholesterol result.

4. National Kidney Foundation. Estimated Glomerular Filtration Rate (eGFR).
What eGFR measures, and why chronic kidney disease so often goes undetected.

5. U.S. Preventive Services Task Force. Thyroid Dysfunction: Screening.
Why the evidence for screening asymptomatic, nonpregnant adults remains insufficient.